Skip to content
10-K

Annual Report

AARDVARK THERAPEUTICS, INC. AARD

0001193125-26-119770

← back to feed
Filed
Mar 23, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 28, 2026 21.82M sh
Shares Diluted FY 2025 · Dec 31, 2025 19.62M sh
Shares Diluted FY 2025 · Dec 31, 2024 4M sh
Capex FY 2025 · Dec 31, 2025 $95K
Capex FY 2025 · Dec 31, 2024 $109K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$54.17M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$18.09M
Short Term Investments FY 2025 · Dec 31, 2025 $62.98M
Short Term Investments FY 2025 · Dec 31, 2024 $12.02M
Cash And Equivalents FY 2025 · Dec 31, 2025 $47.05M
Cash And Equivalents FY 2025 · Dec 31, 2024 $61.64M
Stockholders Equity FY 2025 · Dec 31, 2025 $106.63M
Stockholders Equity FY 2025 · Dec 31, 2024 −$54.64M
Stockholders Equity FY 2025 · Dec 31, 2023 −$34.8M
Current Liabilities FY 2025 · Dec 31, 2025 $10.55M
Current Liabilities FY 2025 · Dec 31, 2024 $4.93M
Total Liabilities FY 2025 · Dec 31, 2025 $10.55M
Total Liabilities FY 2025 · Dec 31, 2024 $5.39M
Current Assets FY 2025 · Dec 31, 2025 $111.89M
Current Assets FY 2025 · Dec 31, 2024 $74.14M
Total Assets FY 2025 · Dec 31, 2025 $117.18M
Total Assets FY 2025 · Dec 31, 2024 $77.51M
Eps Diluted FY 2025 · Dec 31, 2025 −$2.93
Eps Diluted FY 2025 · Dec 31, 2024 −$5.15
Eps Basic FY 2025 · Dec 31, 2025 −$2.93
Eps Basic FY 2025 · Dec 31, 2024 −$5.15
Sga Expense FY 2025 · Dec 31, 2025 $13.79M
Sga Expense FY 2025 · Dec 31, 2024 $5.31M
Rd Expense FY 2025 · Dec 31, 2025 $48.94M
Rd Expense FY 2025 · Dec 31, 2024 $17.36M
Net Income FY 2025 · Dec 31, 2025 −$57.59M
Net Income FY 2025 · Dec 31, 2024 −$20.59M
Operating Income FY 2025 · Dec 31, 2025 −$62.73M
Operating Income FY 2025 · Dec 31, 2024 −$22.79M
Revenue FY 2025 · Dec 31, 2025 $0